Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pharmaceuticals prices

The analysis of the contribution made by increased pharmaceutical spending to the growth in the per capita intensity of health resources suffers from major measurement problems that deprive available indicators of any value. Traditional pharmaceutical price indexes (such as the Laspeyres index, used to calculate the pharmaceutical component of the consumer price index) provide little relevant information in a market in which the introduction of therapeutic innovations is of prime importance the indexes show an apparent freeze, and sometimes even a steep drop (as in the Spanish case). However, the steady rise in the average price per prescription paints a very different picture. [Pg.3]

Despite the existence of direct and indirect mechanisms for pharmaceutical price regulation in most countries, some authors put forward reasons for a growing opposition to the need to regulate prices.2,3 The discussion on the possible lack of justification for drug price regulation policies to improve welfare can be built on three types of argument, which it is important to understand. [Pg.37]

And third, given that regulatory intervention generates both benefits and costs, the benefits of price control might be more than cancelled out (welfare loss) by its costs in the form of administrative costs, transaction costs and distortions in incentives derived from the regulation itself.5 The costs of an imperfect market cannot be compared with those of a perfect one, and pharmaceutical price regulation failures must be taken into account. [Pg.39]

PUBLIC CONTROL OF PHARMACEUTICAL PRICES DOES NOT GUARANTEE LOWER PRICES WHEN THE PATENT EXPIRES... [Pg.54]

Objective The objective of this study is to construct pharmaceutical price indexes in order to be able to make crossnational comparisons and analyse the causes of the differences between countries. [Pg.54]

Conclusions When weighted samples are used that are representative of consumption in each country, the differences in the pharmaceutical price indexes are much smaller than those observed until now. Strict price regulation is related to lower prices for older and more universally distributed compounds. However, generic competition is responsible for notable price reductions in non-regulated markets. [Pg.55]

The implications of the differences in pharmaceutical prices between countries can be far-reaching for any health system with public funding. Let us focus our attention on two aspects. The first of these concerns the capacity of price regulation systems to guarantee low prices without causing excessive harm to incentives to innovate. The second concerns the widespread practice of using observed prices in other countries as a reference for the pricing authorization of new pharmaceuticals. [Pg.56]

Green, D.G. (1997), Editor s introduction is price regulation necessary , in G.D. Green (ed.) et al., Should Pharmaceutical Prices be Regulated , London IEA Health and Welfare Unit, pp. 1-9. [Pg.57]

Abbott III, T.A. (1995), Regulating pharmaceutical prices , in T.A. Abbott III (ed.), Health Care Policy and Regulation, Boston Kluwer Academic Publishers, pp. 105-34. [Pg.57]

Danzon, P.M. (1997), Pharmaceutical Price Regulation National Policies versus Global Interests, Washington AEI Press. [Pg.57]

Mossialos, E. (1998), Pharmaceutical pricing, financing and cost containment in the European Union Member States , in R. Leidl (ed.), Health Care and its Financing in the Single European Market, Amsterdam IOS Press. [Pg.57]

Berndt, E.R. (2000), International comparisons of pharmaceutical prices what do we know, and what does it mean , Journal of Health Economics, 19, 283-7. [Pg.58]

Sargent, J.A. (1987), The politics of the pharmaceutical price regulation scheme , in W. Streek and PC. Schmitter (eds), Private Interest Government Beyond Market and State, London Sage. [Pg.83]

Pavnik, N. (2000), Do pharmaceutical prices respond to insurance , NBER working paper no W7865, Washington, DC, August. [Pg.143]

Systems with freedom of prices These are the countries in which pharmaceutical companies are free to fix the price they see fit for their medicines. This is the case in the USA and the UK. However, freedom of prices does not mean the absence of any type of regulation. Thus, in the UK the Pharmaceutical Price Regulation Scheme6 establishes limits to the return that can be obtained by the companies. Indirectly, this limits the price of the drags. [Pg.151]

The role that economic evaluation can play in pharmaceutical pricing varies with the type of regulation carried out in each country it cannot play the same role in a country such as the USA, where there is freedom of prices, and in a country where pricing is regulated. [Pg.160]

Borrell, J.R. (1999), Pharmaceutical price regulation a study on the impact of the rate-of-retum regulation in the UK , PharmacoEconomics, 15, 291-303. [Pg.233]

In the current, price-sensitive environment, which is the hallmark of modem healthcare and certainly new drug development, expenses necessary to support clinical research are a major concern for sponsors. Both fixed and variable costs can be managed effectively compared to complete in-house development budgets. As product development costs are a significant element influencing pharmaceutical pricing, the role of innovative CROs is expected to grow. [Pg.409]

The regulations do not deal with this point. Companies may charge doctors for products supplied to them on a particular patient basis. There are no general Department of Health restrictions on the levels of price or price increase, as the Pharmaceutical Price Regulation Scheme only governs products with a marketing authorisation. [Pg.386]

Each Member State of the European Union operates its own policy regarding the pricing of pharmaceutical products. In the United Kingdom, the primary tool is the Pharmaceutical Price Regulation Scheme (PPRS), which is better described as a profit-regulating scheme. This is dealt with in detail in Chapter 26. [Pg.532]


See other pages where Pharmaceuticals prices is mentioned: [Pg.815]    [Pg.6]    [Pg.7]    [Pg.14]    [Pg.33]    [Pg.36]    [Pg.37]    [Pg.38]    [Pg.40]    [Pg.41]    [Pg.45]    [Pg.46]    [Pg.51]    [Pg.57]    [Pg.57]    [Pg.80]    [Pg.83]    [Pg.89]    [Pg.150]    [Pg.150]    [Pg.165]    [Pg.271]    [Pg.328]    [Pg.705]    [Pg.706]   
See also in sourсe #XX -- [ Pg.54 , Pg.89 ]




SEARCH



© 2024 chempedia.info